Nashrieh Shimi va Mohandesi Shimi Iran

Nashrieh Shimi va Mohandesi Shimi Iran

Synthesis of Solid Lipid Nanoparticles and Cryoprotectant Effect on Their Size Stabilization

Document Type : Research Article

Author
Parvaneh Pakravan
Department of Chemistry, Zanjan Branch, Islamic Azad University, Zanjan, I.R. IRAN
Abstract
Solid lipid nanoparticles form colloidal drug carrier systems, which are alternative carrier systems to traditional colloidal carriers, such as emulsions, liposomes, and, polymeric micro and nanoparticles. Solid lipid nanoparticles are typically spherical with an average diameter between 1 and 1000 nm, which are dispersed in the water or the aqueous surfactant. Various techniques are used to synthesize these nanoparticles. A variety of methods can be applied to loading different drugs, ranging from hydrophobic to hydrophilic, into lipid nanoparticles. These nanoparticles are used as suitable carriers for drug delivery. However, the physicochemical stability of lipid nanoparticles is one of the major goals for long-term use in the pharmaceutical industry. In this study, the investigations in the presence and absence of cryoprotectants have been considered for the stabilization of the lipid nanoparticles. Studies have shown that 1% concentration of sucrose results in the stability of nanoparticles size after nine months. Also, laboratory release studies revealed no change in release profiles of stabilized lipid nanoparticles.
Keywords
Lipid nanoparticles
Surfactant
Stabilization
Sucrose
cryoprotectant
Drug delivery

Subjects

[1] De Jong W. H., Borm P. JA., Drug delivery and nanoparticles: applications and hazards, Int. j. nanomedicin.3(2): 133-149 (2008).
[2] معاد ی ت.،  قهرمان زاده ر.، یوسفی م.، محمدی ف.، تهیه نانوذره های نقره توسط عصاره چهار گونه گیاهی و بررسی ویژگی های ضد میکروبی آن، نشریه شیمی و مهندسی شیمی ایران، (4)33، 1تا 9، (1393)
[3]  Liu D., Jiang S., Shen H., Qin S., Liu J., Zhang Q., Li R., Xu, Q., Diclofenac sodium-loaded solid lipid nanoparticles prepared by emulsion/solvent evaporation method. J. Nanopart. Res. 13(6): 2375-2386 (2011).
[4]    Han J., Zhao D., Li D., Wang X., Jin Z., Zhao K., Polymer-Based Nanomaterials and Applications for Vaccines and Drugs. Polym. 10(1):31-45 (2018).
[5] He Q., Liu J., Liang J., Liu X., Ding Z, Tuo D., Li W., Sodium Acetate Orientated Hollow/Mesoporous Magnetite Nanoparticles: Facile Synthesis, Characterization and Formation Mechanism, Appl. Sci. 8(2): 292-307 (2018).
[6] Abdelbary G., Fahmy R.H., Diazepam-loaded solid lipid nanoparticles: design and characterization, AAPS Pharm. Sci. Tech. 10(1): 211-219 (2009).
[7] Kheradmandnia S., Vasheghani-Farahani.,Nosrati M., The Effect of Process Variables on the Propertiesof Ketoprofen Loaded Solid Lipid Nanoparticlesof Beeswax and Carnauba Wax, Iran. J. Chem. Chem. Eng. (IJCCE), 29(4): 181-187 (2010).
[8] Wissing S.A., Kayser O., Müller R.H., Solid lipid nanoparticles for parenteral drug delivery. Adv. drug deliv. rev. 56(9): 1257-1272 (2004).
[9] Kaur I. P., Bhandari R., Bhandari S., Kakkar V., Potential of solid lipid nanoparticles in brain targeting. J. Control. Release. 127(2): 97-109 (2008).
[10] Mehnert W., Mäder K., Solid lipid nanoparticles: production, characterization and applications. Adv. drug deliv. rev. 47(2): 165-196 (2001).
[11] Cirri M., Mennini N., Maestrelli F., Mura P., Ghelardini C., di Cesare Mannelli L., Development and in vivo evaluation of an innovative “Hydrochlorothiazide-in Cyclodextrins-in Solid Lipid Nanoparticles” formulation with sustained release and enhanced oral bioavailability for potential hypertension treatment in pediatrics. Int. j. pharm. 521(1): 73-83 (2017).
[12] Li S., Zhao B., Wang F., Wang M., Xie S., Wang S., Han C., Zhu L., Zhou W., Yak interferon-alpha loaded solid lipid nanoparticles for controlled release. Res. Vet. Sci. 88(1): 148-153 (2010).
[13] Martins S., Sarmento B., Ferreira D.C., Souto E.B., Lipid-based colloidal carriers for peptide and protein delivery–liposomes versus lipid nanoparticles, Int. j. nanomedicine. 2(4): 595-607 (2007).
[14] Wong H.L., Bendayan R., Rauth A.M., Li Y., Wu X.Y., Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles, Adv. drug deliv. rev. 59(6): 491-504 (2007).
[15] Garcia-Fuentes M., Alonso M.J., Torres D., Design and characterization of a new drug nanocarrier made from solid–liquid lipid mixtures, J. colloid interface sci. 285(2): 590-598 (2005).
[16] Shah R., Eldridge D., Palombo E., Harding I., Optimisation and stability assessment of solid lipid nanoparticles using particle size and zeta potential, J. Phys. Sci. 25(1): 59-75 (2014).
[17] Mazur A.J., Nowak D., Mannherz H.G., Malicka-Błaszkiewicz M., Methotrexate induces apoptosis in CaSki and NRK cells and influences the organization of their actin cytoskeleton, Eur. J. Pharmacol. 613(1): 24-33 (2009).
[18] Kosasih A., Bowman B.J., Wigent R. J., Ofner C.M., Characterization and in vitro release of methotrexate from gelatin/methotrexate conjugates formed using different preparation variables, Int. j. pharm. 204(1): 81-89 (2000).
[19] Yousefi G.H., Foroutan M., Zarghi A., Shafaati A., Synthesis and Characterization of Methotrexate Polyethylene Glycol Esters as a drug Delivery system,Chem. Pharm. Bull.58(2): 147-153 (2010).
[20] Shukla R., Thomas T.P., Desai A.M., Kotlyar A., Park S.J., Baker J.R., HER2 specific delivery of methotrexate by dendrimer conjugated anti-HER2 mAb, Nanotechnol.19(29): 295102 (2008).
[21] Kashanian S., Azandaryani A.H., Derakhshandeh K., New surface-modified solid lipid nanoparticles using N-glutaryl phosphatidylethanolamine as the outer shell, Int. j. nanomedicine. 6: 2393-2401 (2011).
[22] Stella B., Peira E., Dianzani C., Gallarate M., Battaglia L., Gigliotti C.L., Boggio E., Dianzani U., Dosio, F., Development and Characterization of Solid Lipid Nanoparticles Loaded with a Highly Active Doxorubicin Derivative, Nanomaterials, 8(2): 110-126 (2018).
[23] Chuang S.Y., Lin C.H., Huang T.H., Fang, J.Y., Lipid-Based Nanoparticles as a Potential Delivery Approach in the Treatment of Rheumatoid Arthritis. Nanomaterials, 8(1): 42 (2018).
[24] Naseri N., Valizadeh H., Zakeri-Milani P., Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv. Pharm. Bull. 5(3): 305-313 (2015).
[25] Chaudhary H., Puri N., Kumar V., Solid lipid nanoparticles: An innovative nano-vehicles for drug delivery. Nanosci. Nanotechnol.-Asia, 4(1): 38-44 (2014).
[26] Pathak P., Nagarsenker M., Formulation and evaluation of lidocaine lipid nanosystems for dermal delivery, AAPS Pharm. Sci. Tech. 10(3): 985-992 (2009).
 [27] Zhao Y., Chang Y.X., Hu X., Liu C.Y., Quan L.H., Liao Y.H., Solid lipid nanoparticles for sustained pulmonary delivery of Yuxingcao essential oil: preparation, characterization and in vivo evaluation,Int. j. pharm. 516(1): 364-371(2017).
[28] Cavalli R., Caputo O., Carlotti M.E., Trotta M., Scarnecchia C., Gasco M.R., Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles,Int. j. pharm. 148(1): 47-54 (1997).
[29] Subedi R.K., Kang K.W., Choi H.K., Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin,Eur. J. pharm. Sci. 37(3): 508-513(2009).